BIIB Biogen Inc.

Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

EN
14/09/2016

Underlying

BIIBBiogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

 PRESS RELEASE
Free
BIIB BIOGEN INC.

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Tre...

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specificall...

July 25, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
07/25/25 July 25, 2025 1 EN
 PRESS RELEASE
Free
BIIB BIOGEN INC.

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at ...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Asso...

July 21, 2025 1 EN
 PRESS RELEASE
Free
BIIB BIOGEN INC.

Biogen Announces $2 Billion Manufacturing Investment in North Carolina...

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the compan...

July 21, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
07/18/25 July 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch